The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-positive HER2-negative Non-Metastatic Breast Cancer
Background: Several studies showed the superiority of aromatase inhibitor (AI) as first-line therapy for patients with hormone-receptor (HR)-positive breast cancer (BC). For the clinician, studies in the real-world are warranted to determine treatment based on the efficacy of each drug. We conducte...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2023-01-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1529 |
| _version_ | 1797725100197281792 |
|---|---|
| author | Ria - Etikasari Tri Murti Andayani Dwi Endarti Kartika Widayati Taroeno-Hariadi |
| author_facet | Ria - Etikasari Tri Murti Andayani Dwi Endarti Kartika Widayati Taroeno-Hariadi |
| author_sort | Ria - Etikasari |
| collection | DOAJ |
| description |
Background: Several studies showed the superiority of aromatase inhibitor (AI) as first-line therapy for patients with hormone-receptor (HR)-positive breast cancer (BC). For the clinician, studies in the real-world are warranted to determine treatment based on the efficacy of each drug. We conducted a comparison of 5-y disease-free survival (DFS) of each AI in terms of survival benefit.
Materials and Methods: We evaluated 450 medical records of postmenopausal women at Dr. Sardjito General Hospital who were diagnosed with HR-positive HER2-negative BC (stage I – III) from January to December 2019 and had undergone surgery, received chemotherapy or radiation therapy, and at least one year of anastrozole, letrozole, or exemestane administration. Kaplan Meier estimation survival curve was used to analyse of survival rate.
Result: Of 79 patients meeting inclusion criteria, there were 21.52% distant metastases documented. Time to disease progression of anastrozole, letrozole and exemestane was 49 months, 58 months, and 53 months, respectively. Letrozole was found better than anastrozole (hazard ratio (HR)=4.342, 95% CI 0.95-19.95; p=0.038). Letrozole versus exemestane (HR=2.757, 95% CI 0.53-14.33; p=0,206) and anastrozole versus exemestane (HR=1.652, 95% CI 0.56-4.84; p=0.351) were found not significantly different. 5-y DFS rate of letrozole was better found (87.5%) than exemestane (73.7%) and anastrozole (61,4%).
Conclusion: 5-year letrozole administration could be proposed as first-line therapy for postmenopausal women with HR-positive HER2-negative BC. A considerable subject and long-term follow-up are needed for validation.
|
| first_indexed | 2024-03-12T10:26:15Z |
| format | Article |
| id | doaj.art-05b4ed19d01c48a080ce74603c71cdb7 |
| institution | Directory Open Access Journal |
| issn | 2008-2207 |
| language | English |
| last_indexed | 2024-03-12T10:26:15Z |
| publishDate | 2023-01-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | International Journal of Hematology-Oncology and Stem Cell Research |
| spelling | doaj.art-05b4ed19d01c48a080ce74603c71cdb72023-09-02T09:39:41ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072023-01-0117110.18502/ijhoscr.v17i1.11713The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-positive HER2-negative Non-Metastatic Breast CancerRia - Etikasari0Tri Murti Andayani1Dwi Endarti2Kartika Widayati Taroeno-Hariadi3Doctoral Program, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, IndonesiaDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, IndonesiaDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, IndonesiaDivision of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia Background: Several studies showed the superiority of aromatase inhibitor (AI) as first-line therapy for patients with hormone-receptor (HR)-positive breast cancer (BC). For the clinician, studies in the real-world are warranted to determine treatment based on the efficacy of each drug. We conducted a comparison of 5-y disease-free survival (DFS) of each AI in terms of survival benefit. Materials and Methods: We evaluated 450 medical records of postmenopausal women at Dr. Sardjito General Hospital who were diagnosed with HR-positive HER2-negative BC (stage I – III) from January to December 2019 and had undergone surgery, received chemotherapy or radiation therapy, and at least one year of anastrozole, letrozole, or exemestane administration. Kaplan Meier estimation survival curve was used to analyse of survival rate. Result: Of 79 patients meeting inclusion criteria, there were 21.52% distant metastases documented. Time to disease progression of anastrozole, letrozole and exemestane was 49 months, 58 months, and 53 months, respectively. Letrozole was found better than anastrozole (hazard ratio (HR)=4.342, 95% CI 0.95-19.95; p=0.038). Letrozole versus exemestane (HR=2.757, 95% CI 0.53-14.33; p=0,206) and anastrozole versus exemestane (HR=1.652, 95% CI 0.56-4.84; p=0.351) were found not significantly different. 5-y DFS rate of letrozole was better found (87.5%) than exemestane (73.7%) and anastrozole (61,4%). Conclusion: 5-year letrozole administration could be proposed as first-line therapy for postmenopausal women with HR-positive HER2-negative BC. A considerable subject and long-term follow-up are needed for validation. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1529Aromatase inhibitor; Breast cancer; Disease-free survival; HR-positive; Postmenopause |
| spellingShingle | Ria - Etikasari Tri Murti Andayani Dwi Endarti Kartika Widayati Taroeno-Hariadi The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-positive HER2-negative Non-Metastatic Breast Cancer International Journal of Hematology-Oncology and Stem Cell Research Aromatase inhibitor; Breast cancer; Disease-free survival; HR-positive; Postmenopause |
| title | The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-positive HER2-negative Non-Metastatic Breast Cancer |
| title_full | The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-positive HER2-negative Non-Metastatic Breast Cancer |
| title_fullStr | The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-positive HER2-negative Non-Metastatic Breast Cancer |
| title_full_unstemmed | The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-positive HER2-negative Non-Metastatic Breast Cancer |
| title_short | The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-positive HER2-negative Non-Metastatic Breast Cancer |
| title_sort | 5 year disease free survival of third generation aromatase inhibitor for postmenopausal women with hr positive her2 negative non metastatic breast cancer |
| topic | Aromatase inhibitor; Breast cancer; Disease-free survival; HR-positive; Postmenopause |
| url | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1529 |
| work_keys_str_mv | AT riaetikasari the5yeardiseasefreesurvivalofthirdgenerationaromataseinhibitorforpostmenopausalwomenwithhrpositiveher2negativenonmetastaticbreastcancer AT trimurtiandayani the5yeardiseasefreesurvivalofthirdgenerationaromataseinhibitorforpostmenopausalwomenwithhrpositiveher2negativenonmetastaticbreastcancer AT dwiendarti the5yeardiseasefreesurvivalofthirdgenerationaromataseinhibitorforpostmenopausalwomenwithhrpositiveher2negativenonmetastaticbreastcancer AT kartikawidayatitaroenohariadi the5yeardiseasefreesurvivalofthirdgenerationaromataseinhibitorforpostmenopausalwomenwithhrpositiveher2negativenonmetastaticbreastcancer AT riaetikasari 5yeardiseasefreesurvivalofthirdgenerationaromataseinhibitorforpostmenopausalwomenwithhrpositiveher2negativenonmetastaticbreastcancer AT trimurtiandayani 5yeardiseasefreesurvivalofthirdgenerationaromataseinhibitorforpostmenopausalwomenwithhrpositiveher2negativenonmetastaticbreastcancer AT dwiendarti 5yeardiseasefreesurvivalofthirdgenerationaromataseinhibitorforpostmenopausalwomenwithhrpositiveher2negativenonmetastaticbreastcancer AT kartikawidayatitaroenohariadi 5yeardiseasefreesurvivalofthirdgenerationaromataseinhibitorforpostmenopausalwomenwithhrpositiveher2negativenonmetastaticbreastcancer |